Press Releases
  Date Title View
ROCKVILLE, Md., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported that, on November 14, 2016, it received a letter from the Nasdaq Listing Qualifications Dep...
Posted: Nov 17, 2016
ROCKVILLE, Md., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today provided the following business update. Commercial Update Third quarter 2016 product prescript...
Posted: Nov 14, 2016
ROCKVILLE, Md., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a business update call on Monday, November 14, 2016 at 9:00AM E...
Posted: Nov 11, 2016
ROCKVILLE, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host invest...
Posted: Nov 7, 2016
Study confirms efficacy and tolerability of SPN-812, a novel non-stimulant product, in children with ADHD Study meets primary endpoint with statistically significant reduction in ADHD symptoms Conference call and webcast to discuss results at 9:00 a.m. ET, October 11, 2016 ROCKVILLE, Md., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceutical...
Posted: Oct 11, 2016
ROCKVILLE, Md., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, on Tuesday, October 11, 2016, prior to the market open, it will report the results of its ...
Posted: Oct 10, 2016
ROCKVILLE, Md., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Food and Drug Administration (FDA) has granted tentative approval to the Company's Supp...
Posted: Aug 19, 2016
ROCKVILLE, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Dr. M. James Barrett, Ph.D., has resigned from its Board of Directors effective Augus...
Posted: Aug 12, 2016
Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.Operating income for second quarter 2016 was $10.4 million compared to $3.1 million in the second quarter of 2015.   Diluted earnin...
Posted: Aug 2, 2016
ROCKVILLE, Md., July 20, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the second quarter of 2016 after 5:...
Posted: Jul 20, 2016
1
...
NextLast
= add release to Briefcase